Pathos Enterprises

Pathos is a private, clinical-stage biotechnology company using artificial intelligence, multimodal oncology data, and biological modeling to improve precision oncology drug development. The company combines an AI-enabled development platform with in-licensed oncology assets, aiming to improve patient selection, biomarker discovery, trial design, and development decisions. Its disclosed pipeline includes pocenbrodib, a CBP/p300 inhibitor in Phase 1b/2a for metastatic castration-resistant prostate cancer, and P-500, a brain-penetrant PRMT5 inhibitor with Phase 2-ready positioning for solid tumors including high-grade glioma and uveal melanoma. Pathos also has strategic collaborations with AstraZeneca and Tempus to build a large multimodal oncology foundation model. The company positions itself as a platform-driven precision oncology developer rather than a traditional single-asset biotech.